USA Compression Partners, LP Reports Earnings Results for the First Quarter Ended March 31, 2026

USA Compression Partners, LP announced its earnings results for the first quarter ended March 31, 2026. The company reported significant increases across financial metrics, with sales rising to $309.4 million and revenue to $331.28 million compared to the prior year. Net income more than doubled to $38.34 million, resulting in basic and diluted earnings per share of $0.27.

Original reporting
Published May 5, 2026, 6:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$USAC
Bullish
high confidence
Mentioned
$USAC
alphai data visualization · based on www.marketscreener.com
Decision brief

The 30-second read

$USACBullishMed
01

Why it matters

The positive earnings report could lead to increased investor confidence, potentially driving the stock price higher in the short term. However, sector volatility and macroeconomic factors should be considered.

02

Market read

The earnings results are relevant for investors and traders focusing on energy transportation and related sectors, indicating potential opportunities and risks.

03

What to watch

Potential risks include rising operational costs, regulatory changes, or macroeconomic downturns that could impact future earnings.

Timing: Immediate, as earnings are recent and could influence trading decisions within days to weeks.

Background

USA Compression Partners, LP operates in the energy transportation sector, providing compression services essential for natural gas and oil pipelines. The company's recent earnings reflect operational efficiencies and increased demand.

Company-level read

Ticker impact

$USACBullishHigh confidence
Context

The earnings report indicates strong financial performance, which could positively influence the stock's short-term and medium-term prospects.

Expected impact

Potential upward movement in stock price in the short to medium term.

Evidence & confidence

The strong earnings beat expectations and indicates operational strength, which typically supports higher stock valuations.

Market effects

Positive outlook for the energy transportation sector due to strong earnings reports, potentially boosting sector ETFs and related stocks.

Limited regional impact, primarily affecting US-based energy transport companies.

Moderate, as energy transportation is globally interconnected, but specific to US operations.

Counterpoint

The strong earnings might already be priced in, and future growth could be limited if sector conditions deteriorate or if profit margins face pressure.

Key entities

  • USA Compression Partners, LP

    A provider of compression services for the energy transportation sector.

Related articles

$USACMed

USA Compression Partners Q2 Earnings Call Highlights

USA Compression Partners (NYSE:USAC) reported Q2 metrics including 4.95 million total fleet horsepower, 92% utilization, and average revenue per revenue-generating horsepower per month of $22.84. Adjusted gross margin was 63.5% and leverage was 3.72x. The firm reaffirmed 2026 outlook for adjusted EBITDA $770m-$800m and distributable cash flow $480m-$510m, plus capex guidance.

$USACMed

USA Compression Partners, LP (USAC): Results of Operations and Financial Condition

USA Compression Partners, LP (USAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 usacq22026ex991.htm EX-99.1 Document Exhibit 99.1 News Release USA Compression Partners, LP 8115 Preston Road, Suite 700 Dallas, Texas 75225 usacompression.com USA Compression Partners Reports Second-Quarter 2026 Results DALLAS, Texas, August 4, 2026 — USA Compression P

$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.